Cargando…

Distinct metabolic preference of atypical KRAS mutant

Detalles Bibliográficos
Autor principal:	Cheong, Heesun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661907/ https://www.ncbi.nlm.nih.gov/pubmed/33209906 http://dx.doi.org/10.21037/atm-20-3252

Ejemplares similares

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
por: Allemann, Anna T., et al.
Publicado: (2023)

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
por: Preet, Ranjan, et al.
Publicado: (2018)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
por: Best, Sarah A., et al.
Publicado: (2019)

The Role of Atypical Sexual Preference and Behavior in Neuroelectrophysiological Research of Human Sexual Behavior
por: Ristow, Inka, et al.
Publicado: (2021)

mTORC1 regulates nutrient access in Ras-mediated tumors
por: Cheong, Heesun
Publicado: (2016)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

KRAS inhibitors: going noncovalent
por: Drosten, Matthias, et al.
Publicado: (2022)

Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”
por: Nagasaka, Misako, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
por: Liu, Ke, et al.
Publicado: (2018)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Differentiating atypical parkinsonian syndromes—a way forward?
por: Pfeiffer, Ronald F
Publicado: (2015)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
por: Kerr, Emma, et al.
Publicado: (2016)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

A Clinically Distinct and ‘Atypical’ Subgroup of Head and Neck Cancers Positive for a CpG Island Methylator Phenotype
por: Weisenberger, Daniel J.
Publicado: (2017)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins
por: Goh, Kah Yee, et al.
Publicado: (2020)

Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras
por: Sung, Suhyun, et al.
Publicado: (2015)

Quo vadis, Kras?
por: Schneider, Günter, et al.
Publicado: (2013)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

Mutant KRAS Exosomes Alter the Metabolic State of Recipient Colonic Epithelial Cells
por: Zhang, Qin, et al.
Publicado: (2018)

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
por: Suzuki, Tatsunori, et al.
Publicado: (2021)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Distinctive Klf4 mutants determine preference for DNA methylation status
por: Hashimoto, Hideharu, et al.
Publicado: (2016)

Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism
por: Zhou, Ge, et al.
Publicado: (2014)

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer
por: Nakao, Masayuki, et al.
Publicado: (2020)

Pediatric cerebellar tumors: transcriptionally distinct but developmentally heterogeneous
por: Bhattacharya, Debanjan, et al.
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Understanding KRAS for better targeting
por: Patel, Ronak, et al.
Publicado: (2023)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer
por: Pirlog, Radu, et al.
Publicado: (2022)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v6rfd2pfde5a6ov7vq3tbn12c0